Peplin starts skin cancer clinical trial

By Elaine Rigoli

Tampa, Fla., May 22 - Peplin Ltd. has started an Australian pilot phase 2 clinical trial of its proprietary product PEP005 topical for the treatment of cutaneous squamous cell carcinoma in situ.

"In light of the very positive results we recently reported from our phase 2a clinical trial in superficial basal cell carcinoma where two consecutive days of 0.05% PEP005 topical gel cleared 71% of the skin tumors, we have decided to evaluate the same treatment regimen in patients with cutaneous squamous cell carcinoma in situ," managing director and chief executive officer Michael Aldridge said in a news release.

"In Peplin's original 1999 pilot clinical trial, we saw our best results in squamous cell carcinoma. We would like to see if those results hold up with PEP005 topical. We would expect to announce the results of this trial during the first half of 2007," he said.

Located in Queensland, Australia, Peplin is focused on the development and commercialization of prescription human therapeutic products for the treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.